There are currently four classes of biologics available for the treatment of psoriasis:
- Tumor necrosis factor-alpha (TNF-a) inhibitors: adalimumab (Humira®), certolizumab (Cimzia®), etanercept (Enbrel®), infliximab (Remicade®)
- Interleukin-12/interleukin-23 (IL-12/IL-23) inhibitors: ustekinumab
- Interleukin-17 (IL-17) inhibitors: secukinumab (Cosentyx®), ixekizumab (Taltz®), brodalumab (Siliq™)
- Interleukin-23 (IL-23) inhibitors: tildrakizumab (Ilumya™), Risankizusmab (Skyziri™), and guselkumab (Tremfya®)
Biologics may also improve a person's quality of life (calculated using a questionnaire about how happy and healthy a person is feeling). Biologics that inhibit T cells that cause psoriasis also allow for a treatment-free period. Since the effects of biologics last even after the medication is stopped, people with psoriasis can take "drug holidays" in between treatment periods. This may reduce the risk of side effects and also frees the person from taking regular drug treatment.
All material copyright MediResource Inc. 1996 – 2022. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Source: www.medbroadcast.com/healthfeature/gethealthfeature/Psoriasis-Treatment-Biologics